7Baggers

Royalty Pharma plc Quarterly Balance Sheets Chart

Quarterly
 | 
Annual
 
 Goodwill  
 Cash and Cash Eq  
 Long-Term Debt  
20200930 20201231 20210331 20210630 20210930 20211231 20220331 20220630 20220930 20221231 20230331 20230630 20230930 20231231 20240331 20240630 20240930 20241231 20250331 20250630 01.092.173.264.345.436.527.6Billion

Royalty Pharma plc Quarterly Balance Sheets Table

Quarterly
 | 
Annual
 
Unit: USD2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 
                       
  assets                     
  current assets                     
  cash and cash equivalents631,908,000 1,087,720,000 929,026,000 950,052,000 1,764,644,000 843,000,000 477,010,000 936,448,000 2,173,077,000 1,975,689,000 1,710,751,000 991,628,000 2,108,037,000 1,791,517,000 1,541,048,000 1,800,808,000 1,142,281,000 708,810,000 1,008,680,000 1,552,802,000 2,443,430,000 
  financial royalty assets842,938,000 716,559,000 783,770,000 765,773,000 750,098,000 660,482,000 738,438,000 742,160,000 729,910,000 610,022,000 691,319,000 675,857,000 639,244,000 570,684,000 614,351,000 579,746,000 596,851,000 522,388,000 587,193,000 556,856,000 526,937,000 
  available for sale debt securities13,200,000 12,100,000 58,200,000 48,500,000 38,500,000 29,000,000 18,300,000 5,300,000 5,100,000 2,500,000 1,300,000 409,347,000 363,700,000 64,800,000 66,000,000 67,016,000 68,702,000 69,261,000 69,984,000 43,507,000 28,500,000 
  other royalty income receivable27,743,000 23,785,000 26,956,000 24,901,000 23,580,000 22,227,000 22,405,000 21,553,000 18,870,000 22,084,000 19,767,000 19,131,000 17,315,000 14,618,000 15,023,000 13,844,000 10,694,000 6,541,000 6,011,000 4,389,000 3,147,000 
  other current assets4,452,000 3,079,000 4,187,000 4,969,000 2,292,000 5,010,000 3,798,000 6,784,000 10,224,000 4,570,000 90,520,000 90,515,000 67,119,000 5,388,000 6,631,000 8,945,000 12,098,000 6,657,000 8,596,000 14,398,000 12,789,000 
  total current assets1,520,241,000 1,843,243,000 1,802,139,000 1,794,195,000 2,579,114,000 1,559,719,000 1,274,193,000 1,728,605,000 2,953,539,000 2,631,221,000 2,554,908,000 2,342,116,000 3,503,849,000 2,982,418,000 2,878,211,000 2,775,761,000 2,707,454,000 2,416,024,000 2,696,898,000 2,783,851,000 3,390,789,000 
  equity securities110,529,000 141,083,000 186,960,000 228,867,000 178,017,000 277,217,000 199,487,000 144,342,000 142,800,000 101,529,000 112,348,000 262,820,000 304,447,000 267,638,000 269,800,000 264,765,000 184,042,000 244,503,000 298,689,000 637,411,000 477,185,000 
  equity method investments275,914,000 336,208,000 379,424,000 351,017,000 352,099,000 350,355,000 375,894,000 378,291,000 384,301,000 384,325,000 397,175,000 409,857,000 412,076,000 418,151,000        
  goodwill924,634,000                     
  other assets85,491,000 36,707,000 33,534,000 42,789,000 27,555,000 4,488,000 6,522,000 20,212,000 29,408,000 28,030,000 29,629,000 30,613,000 33,412,000 3,870,000 4,145,000 4,515,000 5,960,000 4,256,000 23,158,000 4,891,000  
  total assets18,323,000,000 17,608,256,000 18,222,715,000 18,042,242,000 17,656,579,000 16,130,886,000 16,381,851,000 15,855,524,000 17,121,482,000 17,074,121,000 16,813,466,000 17,672,605,000 17,740,413,000 17,378,888,000 17,515,865,000 17,732,358,000 16,514,913,000 15,914,088,000 16,020,286,000 15,990,678,000 15,685,556,000 
  liabilities and shareholders’ equity                     
  current liabilities                     
  distributions payable to non-controlling interests98,197,000 108,796,000          105,731,000 115,990,000 116,010,000        
  accounts payable and accrued liabilities20,209,000                     
  interest payable85,609,000 19,221,000 98,062,000 38,412,000 56,252,000 12,595,000 51,682,000 12,595,000 54,162,000 13,199,000 54,162,000 13,199,000 54,162,000 13,199,000 57,696,000 16,733,000 42,904,000 10,271,000 42,146,000   
  current portion of long-term debt999,436,000 998,605,000 997,773,000 996,942,000     999,370,000 998,441,000 997,512,000 996,583,000         182,226,000 
  other current liabilities3,075,000 18,600,000 68,600,000 31,200,000 97,493,000 9,019,000 11,375,000    12,400,000      4,314,000     
  total current liabilities1,206,526,000 1,182,852,000 1,253,616,000 1,167,758,000 275,701,000 124,574,000 161,377,000 127,933,000 1,172,222,000 1,116,879,000 1,166,783,000 1,131,625,000 182,327,000 135,871,000 171,250,000 255,055,000 283,989,000 255,983,000 307,887,000 269,983,000 450,973,000 
  long-term debt7,003,063,000 6,618,847,000 6,614,653,000 6,610,437,000 7,602,019,000 6,139,376,000 6,135,285,000 6,131,194,000 6,127,074,000 6,122,942,000 6,118,810,000 6,114,677,000 7,106,199,000 7,101,138,000 7,096,070,000 7,090,669,000 5,825,559,000 5,821,072,000 5,816,584,000 5,812,047,000 5,729,622,000 
  accrued compensation liabilities467,143,000                     
  other liabilities143,328,000 17,900,000 12,080,000 5,580,000 27,041,000 3,220,000 900,000 11,300,000 8,500,000 12,300,000 2,500,000 9,900,000 43,700,000       110,000,000 110,000,000 
  total liabilities8,820,060,000 7,819,599,000 7,880,349,000 7,783,775,000 7,904,761,000 6,267,170,000 6,297,562,000 6,270,427,000 7,307,796,000 7,252,121,000 7,288,093,000 7,256,202,000 7,332,226,000 7,237,009,000 7,267,320,000 7,345,724,000 6,109,548,000 6,077,055,000 6,124,471,000 6,192,030,000 6,290,595,000 
  commitments and contingencies                     
  shareholders’ equity                     
  class a ordinary shares, 0.0001 par value; issued and outstanding: 2025–432,288 and 2024–445,98544,000                     
  class b ordinary shares, 0.000001 par value; issued and outstanding: 2025–150,881 and 2024–143,128                     
  class r redeemable shares, £1 par value; issued and outstanding: 2025–50 and 2024–5063,000 63,000                    
  deferred shares, 0.000001 par value; issued and outstanding: 2025–409,032 and 2024–392,255                     
  additional paid-in capital4,127,665,000 4,210,531,000 4,103,482,000 4,107,742,000 4,100,554,000 4,074,849,000 4,011,435,000 4,006,758,000 4,031,242,000 3,739,658,000 3,666,160,000 3,632,903,000 3,570,585,000 3,543,204,000 3,507,533,000 3,454,218,000 3,415,598,000 2,931,249,000 2,865,964,000 2,611,976,000 2,557,237,000 
  retained earnings2,222,750,000 2,480,664,000 2,845,653,000 2,764,685,000 2,378,251,000 2,427,448,000 2,517,583,000 2,134,680,000 2,252,945,000 2,216,811,000 1,964,689,000 2,504,974,000 2,446,132,000 2,224,677,000 2,255,179,000 2,320,878,000 2,291,966,000 1,923,771,000 1,920,635,000 1,807,146,000 1,571,399,000 
  non-controlling interests3,155,030,000 3,100,010,000 3,395,785,000 3,388,589,000 3,275,566,000 3,363,965,000 3,557,792,000 3,446,175,000 3,532,019,000 3,868,251,000 3,897,223,000 4,264,303,000 4,380,938,000 4,364,324,000        
  treasury interests-2,612,000 -2,654,000 -2,662,000 -2,657,000 -2,661,000 -2,654,000 -2,629,000 -2,624,000 -2,629,000 -2,828,000 -2,806,000 -2,788,000 -2,752,000 -2,736,000 -2,715,000 -2,685,000 -2,662,000 -2,359,000 -2,317,000 -2,155,000 -2,119,000 
  total shareholders’ equity9,502,940,000 9,788,657,000 10,342,366,000 10,258,467,000 9,751,818,000 9,863,716,000 10,084,289,000 9,585,097,000 9,813,686,000 9,822,000,000 9,525,373,000 10,416,403,000 10,408,187,000 10,141,879,000 10,248,545,000 10,386,634,000 10,405,365,000 9,837,033,000    
  total liabilities and shareholders’ equity18,323,000,000 17,608,256,000 18,222,715,000 18,042,242,000 17,656,579,000 16,130,886,000 16,381,851,000 15,855,524,000 17,121,482,000 17,074,121,000 16,813,466,000 17,672,605,000 17,740,413,000 17,378,888,000 17,515,865,000 17,732,358,000 16,514,913,000 15,914,088,000    
  accounts payable and accrued expenses 37,630,000 13,370,000 22,055,000 23,416,000 11,551,000 15,165,000 13,627,000 5,809,000 6,657,000 7,906,000 16,112,000 12,175,000 6,662,000 5,620,000 9,187,000 9,393,000 8,272,000 10,775,000 24,388,000 34,366,000 
  class a ordinary shares, 0.0001 par value; issued and outstanding: 2025–425,590 and 2024–445,985 43,000                    
  class b ordinary shares, 0.000001 par value; issued and outstanding: 2025–140,870 and 2024–143,128                     
  deferred shares, 0.000001 par value; issued and outstanding: 2025–394,513 and 2024–392,255                     
  distributions payable to legacy non-controlling interests  75,811,000 79,149,000 98,540,000 91,409,000 83,155,000 101,711,000 112,881,000 98,582,000 94,803,000           
  class a ordinary shares, 0.0001 par value; issued and outstanding: 2024–445,985 and 2023–446,692  45,000                   
  class b ordinary shares, 0.000001 par value; issued and outstanding: 2024–143,128 and 2023–150,743                     
  class r redeemable shares, £1 par value; issued and outstanding: 2024–50 and 2023–50  63,000 63,000 63,000 63,000                
  deferred shares, 0.000001 par value; issued and outstanding: 2024–392,255 and 2023–384,640                     
  class a ordinary shares, 0.0001 par value; issued and outstanding: 2024–446,038 and 2023–446,692   45,000                  
  class b ordinary shares, 0.000001 par value; issued and outstanding: 2024–144,881 and 2023–150,743                     
  deferred shares, 0.000001 par value; issued and outstanding: 2024–390,502 and 2023–384,640                     
  class a ordinary shares, 0.0001 par value; issued and outstanding: 2024–449,065 and 2023–446,692    45,000                 
  class b ordinary shares, 0.000001 par value; issued and outstanding: 2024–145,328 and 2023–150,743                     
  deferred shares, 0.000001 par value; issued and outstanding: 2024–390,055 and 2023–384,640                     
  class a ordinary shares, 0.0001 par value; issued and outstanding: 2024–450,981 and 2023–446,692     45,000                
  class b ordinary shares, 0.000001 par value; issued and outstanding: 2024–146,456 and 2023–150,743                     
  deferred shares, 0.000001 par value; issued and outstanding: 2024–388,927 and 2023–384,640                     
  marketable securities          24,421,000 139,926,000 290,402,000 484,221,000 581,872,000 245,745,000 842,685,000 1,068,913,000 983,279,000 579,527,000 343,679,000 
  accrued royalty receivable      14,242,000 16,360,000 16,358,000 16,356,000 16,830,000 15,712,000 18,032,000 51,190,000 53,286,000 59,657,000 34,143,000 33,454,000 33,155,000 32,372,000 32,307,000 
  class a ordinary shares, 0.0001 par value; issued and outstanding: 2023–446,692 and 2022–443,166      45,000               
  class b ordinary shares, 0.000001 par value; issued and outstanding: 2023–150,743 and 2022–164,058                     
  class r redeemable shares, £1 par value; issued and outstanding: 2023–50 and 2022–50      63,000 63,000 63,000             
  deferred shares, 0.000001 par value; issued and outstanding: 2023–384,640 and 2022–371,325                     
  class a ordinary shares, 0.0001 par value; issued and outstanding: 2023–445,843 and 2022–443,166       45,000              
  class b ordinary shares, 0.000001 par value; issued and outstanding: 2023–152,546 and 2022–164,058                     
  deferred shares, 0.000001 par value; issued and outstanding: 2023–382,837 and 2022–371,325                     
  class a ordinary shares, 0.0001 par value; issued and outstanding: 2023–450,352 and 2022–443,166        46,000             
  class b ordinary shares, 0.000001 par value; issued and outstanding: 2023–152,896 and 2022–164,058                     
  deferred shares, 0.000001 par value; issued and outstanding: 2023–382,487 and 2022–371,325                     
  class a ordinary shares, 0.0001 par value; 448,287 and 443,166 issued and outstanding, respectively         45,000            
  class b ordinary shares, 0.000001 par value; 158,939 and 164,058 issued and outstanding, respectively                     
  class r redeemable shares, £1 par value; 50 and 50 issued and outstanding, respectively         63,000 63,000 63,000 63,000 63,000 63,000 63,000 63,000 63,000    
  deferred shares, 0.000001 par value; 376,444 and 371,325 issued and outstanding, respectively                     
  intangible royalty assets              5,670,000 11,466,000 17,262,000 22,995,000 28,666,000 34,462,000 40,258,000 
  class a ordinary shares, 0.0001 par value; 443,166 and 432,963 issued and outstanding, respectively          44,000           
  class b ordinary shares, 0.000001 par value; 164,058 and 174,213 issued and outstanding, respectively                     
  deferred shares, 0.000001 par value, 371,325 and 361,170 issued and outstanding, respectively                     
  accumulated other comprehensive income           16,904,000 13,177,000 12,304,000 16,491,000 20,553,000 28,672,000 29,452,000 34,395,000 34,746,000 30,515,000 
  class a ordinary shares, 0.0001 par value; 441,104 and 432,963 issued and outstanding, respectively           44,000          
  class b ordinary shares, 0.000001 par value; 166,118 and 174,213 issued and outstanding, respectively                     
  deferred shares, 0.000001 par value; 369,265 and 361,170 issued and outstanding, respectively                     
  class a ordinary shares, 0.0001 par value; 437,139 and 432,963 issued and outstanding, respectively            44,000         
  class b ordinary shares, 0.000001 par value; 170,081 and 174,213 issued and outstanding, respectively                     
  deferred shares, 0.000001 par value; 365,302 and 361,170 issued and outstanding, respectively                     
  class a ordinary shares, 0.0001 par value; 435,316 and 432,963 issued and outstanding, respectively             43,000        
  class b ordinary shares, 0.000001 par value; 171,862 and 174,213 issued and outstanding, respectively                     
  deferred shares, 0.000001 par value; 363,521 and 361,170 issued and outstanding, respectively                     
  investments in non-consolidated affiliates              435,394,000 473,051,000 465,620,000 444,407,000 454,936,000 439,839,000 430,296,000 
  liabilities and equity                     
  distribution payable to non-controlling interest              107,934,000 119,135,000 117,378,000 108,840,000 126,366,000 135,595,000  
  accrued purchase obligation               110,000,000 110,000,000 110,000,000 110,000,000 110,000,000 111,610,000 
  class a ordinary shares, 0.0001 par value; 432,963 and 388,135 issued and outstanding, respectively              43,000       
  class b ordinary shares, 0.000001 par value; 174,213 and 218,976 issued and outstanding, respectively                     
  deferred shares, 0.000001 par value, 361,170 and 316,407 issued and outstanding, respectively                     
  non-controlling interest              4,471,951,000 4,593,564,000 4,671,686,000 4,954,818,000 5,077,036,000 5,346,835,000 5,237,829,000 
  class a ordinary shares, 0.0001 par value; 429,511 and 388,135 issued and outstanding, respectively               43,000      
  class b ordinary shares, 0.000001 par value; 177,663 and 218,976 issued and outstanding, respectively                     
  deferred shares, 0.000001 par value, 357,720 and 316,407 issued and outstanding, respectively                     
  class a ordinary shares, 0.0001 par value; 427,006 and 388,135 issued and outstanding, respectively                42,000     
  class b ordinary shares, 0.000001 par value; 180,166 and 218,976 issued and outstanding, respectively                     
  deferred shares, 0.000001 par value, 355,217 and 316,407 issued and outstanding, respectively                     
  derivative financial instruments                 2,884,000 5,439,000 7,629,000 14,717,000 
  milestone payable                 18,600,000 18,600,000   
  class a ordinary shares, 0.0001 par value; 392,857 and 388,135 issued and outstanding, respectively                 39,000    
  class b ordinary shares, 0.000001 par value; 214,255 and 218,976 issued and outstanding, respectively                     
  deferred shares, 0.000001 par value, 321,128 and 316,407 issued and outstanding, respectively                     
  shareholders’/unitholders’ equity                     
  shareholders’ contributions                     
  class a ordinary shares, 0.0001 par value; 388,135 and 0 issued and outstanding, respectively                  39,000   
  class b shares, 0.000001 par value; 218,976 and 0 issued and outstanding, respectively                     
  class r redeemable shares, £1 par value; 50 and 0 issued and outstanding, respectively                  63,000 63,000 63,000 
  deferred shares, 0.000001 par value, 316,407 and 0 issued and outstanding, respectively                     
  total shareholders’/unitholders’ equity                  9,895,815,000 9,798,648,000  
  total liabilities and shareholders’/unitholders’ equity                  16,020,286,000 15,990,678,000  
  class a ordinary shares, 0.0001 par value; 370,002 and 0 issued and outstanding, respectively                   37,000  
  class b shares, 0.000001 par value; 237,108 and 0 issued and outstanding, respectively                     
  deferred shares, 0.000001 par value, 298,275 and 0 issued and outstanding, respectively                     
  royalty distribution payable to affiliates                    122,771,000 
  shareholders'/unitholders' equity                     
  shareholders' contributions                     
  class a ordinary shares, 0.0001 par value; 365,899 and 0 issued and outstanding, respectively                    37,000 
  class b shares, 0.000001 par value; 241,207 and 0 issued and outstanding, respectively                     
  deferred shares, 0.000001 par value, 294,176 and 0 issued and outstanding, respectively                     
  total shareholders'/unitholders' equity                    9,394,961,000 
  total liabilities and shareholders'/unitholders' equity                    15,685,556,000 

We provide you with 20 years of balance sheets for Royalty Pharma plc stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Royalty Pharma plc. Explore the full financial landscape of Royalty Pharma plc stock with our expertly curated balance sheets.

The information provided in this report about Royalty Pharma plc stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.